Relevant bibliographies by topics / HL-1 buňky

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'HL-1 buňky'

Author: Grafiati
Published: 28 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HL-1 buňky.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HL-1 buňky"

1

Pophali, Priyanka A., Lisa A. Rybicki, Kathleen B. Fenner, et al. "Bulky Disease Does Not Adversely Affect Overall Survival in Early Stage Hodgkin Lymphoma: Role of Interim PET and Possible Omission of Radiotherapy in Select Patients." Blood 124, no. 21 (2014): 4428. http://dx.doi.org/10.1182/blood.v124.21.4428.4428.

Full text
Abstract:
Abstract Background: Bulky disease is considered a major driver of unfavorable prognosis in early stage Hodgkin Lymphoma (HL). Treatment guidelines for bulky early stage HL call for more aggressive initial therapy compared to non-bulky disease. There are limited data on outcomes in bulky disease, particularly in patients treated with chemotherapy alone, or on the utility of interim PET scans. We retrospectively analyzed data on patients with early stage HL to assess the impact of disease bulk, interim PET and treatment modality on outcomes. Methods: We reviewed charts of 151 consecutive patien
APA, Harvard, Vancouver, ISO, and other styles
2

Ngeow, J. Y., R. Quek, M. Tao, et al. "Analysis of long-term treatment outcomes and toxicty of HL." Journal of Clinical Oncology 27, no. 15_suppl (2009): e19536-e19536. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19536.

Full text
Abstract:
e19536 Background: Prognosis of patients with Hodgkin lymphoma (HL) has substantially improved but therapy of HL can however contribute to delayed toxicity. Long term treatment outcomes of HL in our local population were evaluated. Methods: Clinical and treatment data was prospectively collected from all patients with a histological diagnosis of HL. Patients were all fully staged with CT scan and bone marrow biopsy. Results: On the basis of 217 patients seen at the National Cancer Centre Singapore between 1990–2008, we found that there was a peak in young adulthood with 103 patients who were d
APA, Harvard, Vancouver, ISO, and other styles
3

Abd-Elrahman, Ihab, Vladimir Rapoport, Tzahi Neuman, et al. "Clinical and Molecular Significance of Tumor Necrosis In Newly Diagnosed Patients with Hodgkin's Lymphoma and Diffuse Large B Cell Lymphoma." Blood 116, no. 21 (2010): 1995. http://dx.doi.org/10.1182/blood.v116.21.1995.1995.

Full text
Abstract:
Abstract Abstract 1995 Lymphoma of various types in newly diagnosed patients may exhibit necrotic areas in the tumor mass on imaging. To date, little is known about the clinical significance of this finding and even less is known about the mechanism of cell death in the necrotic tissue - apoptosis, molecular necrosis or autophagy. The objective of this study was to investigate the prognostic significance of tumor necrosis in newly diagnosed Hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) patients and to define the molecular mechanism of cell death responsible for the necrosis
APA, Harvard, Vancouver, ISO, and other styles
4

Tartas, Norma, Marta Zerga, Graciela Alfonso, et al. "More Than 4 Cycles of ABVD for the Treatment of Stage I–II Hodgkin’s Lymphoma?." Blood 106, no. 11 (2005): 4719. http://dx.doi.org/10.1182/blood.v106.11.4719.4719.

Full text
Abstract:
Abstract Patients with stage I-II A non bulky Hodgkin’s lymphoma (HL) are successfully treated with 2–4 cycles of ABVD plus IF radiotherapy (RT). Although the negative impact in DFS and OS of B symptoms and bulky disease(X) is widely accepted, other risk factors such as number of lymph node regions involved or extensive spleen involvement have also been reported. What is the best treatment for such patients? Is radiotherapy necessary? We report here our experience with protocol HD 98 in 62 patients, with stage I–II HL. Since January 98 we have included 30 individuals without risk factors and 3
APA, Harvard, Vancouver, ISO, and other styles
5

Canellos, George P. "Chemotherapy Alone for Localized Non-Bulky Hodgkin Lymphoma." Blood 112, no. 11 (2008): 2591. http://dx.doi.org/10.1182/blood.v112.11.2591.2591.

Full text
Abstract:
Abstract Combined modality therapy with radiation and chemotherapy has been the standard treatment for limited-stage HL. Long-term toxicities, including cardiac and disease and secondary cancers, s have been reported in multiple series with long follow-up. Lower doses and smaller fields may be less toxic, but mediastinal/cardiac radiation is unavoidable in most cases. The Dana-Farber Cancer Institute and Massachusetts General Hospital lymphoma teams have now treated 74 patients with localized, non-bulky classical HL with chemotherapy as the only therapy. The median age of the series was 29 yea
APA, Harvard, Vancouver, ISO, and other styles
6

Linardi, Camila C. G., Luis Fernando Pracchia, Rodrigo Dolphini Velasques, Claudia Bitti Barroso, and Valeria Buccheri. "Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution." Blood 118, no. 21 (2011): 3153. http://dx.doi.org/10.1182/blood.v118.21.3153.3153.

Full text
Abstract:
Abstract Abstract 3153 Hodgkin Lymphoma (HL) is characterized by high cure rates. Approximately 90% early stage and 60–70% advanced stage patients have long term disease free survival. In Brazil it is observed that about 60% of patients present with advanced stage, while in developed countries about 40% belong to this group. The aim of this retrospective study was to analyze data of patients with HL from the Oncohematology Unit of University of São Paulo- Medical School and evaluate the event free survival (EFS) and the overall survival (OS) according to clinical stage. We included all consec
APA, Harvard, Vancouver, ISO, and other styles
7

Park, Steven I., Kristy L. Richards, Oludamilola Olajide, et al. "A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma." Blood 124, no. 21 (2014): 4431. http://dx.doi.org/10.1182/blood.v124.21.4431.4431.

Full text
Abstract:
Abstract Background: Treatment of Hodgkin lymphoma (HL) requires a careful balance between providing enough therapy to cure the disease and avoiding unnecessary treatment that could result in excessive long-term treatment-related complications. The preferred treatment option for limited stage non-bulky HL currently involves the use of combined chemotherapy and involved-field radiation therapy. Given the unclear overall survival advantage and the long-term side effects associated with consolidative radiation, the use of this modality remains one of the most controversial topics in the treatment
APA, Harvard, Vancouver, ISO, and other styles
8

Savage, Kerry J., Joseph M. Connors, Don Wilson, et al. "FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan." Blood 110, no. 11 (2007): 213. http://dx.doi.org/10.1182/blood.v110.11.213.213.

Full text
Abstract:
Abstract Consolidative radiotherapy (RT) is often administered following chemotherapy for advanced stage Hodgkin lymphoma (HL) with bulky disease at diagnosis or for residual abnormalities on post-chemotherapy CT imaging. It is unknown whether RT is necessary for such patients if the residual mass is FDG-PET-negative (PET-neg) following chemotherapy (CHT). Further, it has been previously shown that a post-therapy PET-positive (PET-pos) scan is highly predictive of future relapse; however, it is unclear whether consolidative RT can be used to salvage these cases. Methods Since July 2005, adult
APA, Harvard, Vancouver, ISO, and other styles
9

Gallamini, Andrea, Andrea Bianchi, Anna Borra, et al. "Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease." Journal of Clinical Oncology 30, no. 15_suppl (2012): 8077. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8077.

Full text
Abstract:
8077 Background: Interim 18F-FDG-PET (iPET) is the most important prognosticator in advanced-stage ABVD-treated Hodgkin Lymphoma (HL), but in early stage w/ or w/o bulky lesion a low PPV of iPET was reported. Dual-point PET scan (2P-PET) has been used to discriminate unspecific inflammatory from neoplastic FDG uptake. At the Tx end, with a single FDG-avid mass (SFAM), the specificity of PET in Tx response evaluation was sub-optimal. We report here preliminary results from a cohort of HL patients (p) presenting with bulky lesions, scanned with 2P-PET with the aim to increase specificity and PPV
APA, Harvard, Vancouver, ISO, and other styles
10

Balhara, Kirti, Sarika Singh, Shyamlata Jain, M. K. Daga, and Anubhav Vindal. "Epstein Barr Virus in Hodgkin’s Lymphoma a Path Less Treaded: An Observational Study." Annals of Pathology and Laboratory Medicine 7, no. 6 (2020): A311–319. http://dx.doi.org/10.21276/apalm.2845.

Full text
Abstract:
Background: Epstein-Barr virus (EBV) is a ubiquitous virus belonging to γ-Herpesvirus subfamily, infecting B cells, T cells, Natural killer (NK) cells & causes both benign and malignant diseases. It has been detected in large subset of Hodgkin lymphoma (HL) cases around the world, especially in countries with poor socioeconomic conditions and among younger age. Limited studies are available reflecting the Indian scenario of HL and EBV association. EBV positivity in Indian HL varies from 28-97% Majority of these studies employed Immunohistochemistry (IHC) for LMP1, a few performed In Situ H
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "HL-1 buňky"

1

Slavík, Jan. "Zarovnání excitabilních buněk na multielektrodových polích." Doctoral thesis, Vysoké učení technické v Brně. CEITEC VUT, 2021. http://www.nusl.cz/ntk/nusl-442346.

Full text
Abstract:
Práce se zabývá zarovnáváním excitabilních buněk na multielektrodových polích. Nejprve bylo analyzováno zarovnávání excitabilních buněk. Byly použity embryonální neurony z hippocampusu potkanů a HL-1 buňky, které jsou odvozeny z AT-1 linie nádorových myších atriálních kardiomyocytů. Zarovnávání bylo testováno na drážkovaných površích a na površích s materiály s různou buněčnou afinitou. Bylo prokázáno, že na drážkových površích se ve směru drážek zarovnávají neurony i HL-1 buňky, ale na površích s různou chemickou affinitou se zarovnávají pouze neurony. Dále byly vyrobeny vlastní multielektrod
APA, Harvard, Vancouver, ISO, and other styles
2

Biriczová, Lilla. "Význam opioidních a TLR-4 receptorů v mechanismu působení opioidů na srdeční svalové buňky." Master's thesis, 2020. http://www.nusl.cz/ntk/nusl-435845.

Full text
Abstract:
It has been reported that opioid receptor activation mimics ischemic preconditioning, which may protect the heart from the development of infarction. Toll-like receptor 4 (TLR-4) during infarction stimulates cytokine production leading to inflammation and injury of the heart tissue. Our aim was to study the effect of morphine in vitro on the viability and oxidative state of H9c2 cells (rat cardiomyoblasts) and the role of TLR-4 during oxidative stress. Our experiments showed that pretreatment with morphine before tert-butylhydroperoxide (t-BHP)-, 2,2'-bipyridyl (BP)- and lipopolysaccharide (LP
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography